{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:43:33Z","timestamp":1761101013130},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1007\/bf03165082","type":"journal-article","created":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T07:15:00Z","timestamp":1254294900000},"page":"29-34","source":"Crossref","is-referenced-by-count":9,"title":["Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis"],"prefix":"10.1007","volume":"76","author":[{"given":"H. Joachim","family":"Deeg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Guardiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03165082_CR1","first-page":"1106","volume-title":"Hematology Basic Principles and Practice","author":"PL Greenberg","year":"2000","unstructured":"Greenberg PL. Myelodysplastic syndrome. In: Hoffman R, Benz EJ, Shattil SJ, et al. eds.,Hematology Basic Principles and Practice. New York: Churchill Livingstone, 2000:1106\u20131129."},{"key":"BF03165082_CR2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","volume":"74","author":"GF Sanz","year":"1989","unstructured":"Sanz GF, Sanz MA, Vallesp T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients.Blood. 1989;74:395\u2013408.","journal-title":"Blood."},{"key":"BF03165082_CR3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes.Br J Haematol. 1982;51:189\u2013199.","journal-title":"Br J Haematol."},{"key":"BF03165082_CR4","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes (published erratum appears in Blood 1998;91:1100).Blood. 1997;89:2079\u20132088.","journal-title":"Blood."},{"key":"BF03165082_CR5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V87.1.51.51","volume":"87","author":"JE Anderson","year":"1996","unstructured":"Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors.Blood. 1996;87:51\u201358.","journal-title":"Blood."},{"key":"BF03165082_CR6","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1200\/JCO.1995.13.12.2973","volume":"13","author":"MR O\u2019Donnell","year":"1995","unstructured":"O\u2019Donnell MR, Long GD, Parker PM, et al. Busulfan\/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia.J Clin Oncol. 1995; 13:2973\u20132979.","journal-title":"J Clin Oncol."},{"key":"BF03165082_CR7","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1182\/blood.V81.8.2194.2194","volume":"81","author":"V Ratanatharathom","year":"1993","unstructured":"Ratanatharathom V, Karanes C, Uberti J, et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes.Blood. 1993;81:2194\u20132199.","journal-title":"Blood."},{"issue":"suppl 1)","key":"BF03165082_CR8","first-page":"659a","volume":"92","author":"JE Amderson","year":"1998","unstructured":"Amderson JE, Appelbaum FR, Barnett T, Chauncey TR, Flowers M, Storb R. Relapse after allogeneic bone marrow transplantation (BMT) for myelodysplasia (MDS) subtype refractory anemia (RA) is increased by shielding lungs and liver during irradiation [abstract].Blood. 1998;92(suppl 1):659a.","journal-title":"Blood."},{"key":"BF03165082_CR9","first-page":"445","volume":"10","author":"TJ Nevill","year":"1992","unstructured":"Nevill TJ, Shepherd JD, Reece DE, et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT.Bone Marrow Transplant. 1992;10:445\u2013450.","journal-title":"Bone Marrow Transplant"},{"key":"BF03165082_CR10","first-page":"157","volume":"98","author":"C Hsu","year":"1999","unstructured":"Hsu C, Lin MT, Tang JL, Tien HF, Wang CH, Chen YC. Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome.Journal of the Formosan Medical Association. 1999;98:157\u2013164.","journal-title":"Journal of the Formosan Medical Association"},{"key":"BF03165082_CR11","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood.V99.6.1943","volume":"99","author":"H Castro-Malaspina","year":"2002","unstructured":"Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program.Blood. 2002;99:1943\u20131951.","journal-title":"Blood."},{"issue":"suppl 1","key":"BF03165082_CR12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0145-2126(97)81374-4","volume":"21","author":"JE Anderson","year":"1997","unstructured":"Anderson JE, Thomas ED. The Seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS) [abstract].Leuk Res. 1997;21(suppl 1):S51.","journal-title":"Leuk Res."},{"key":"BF03165082_CR13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00062752-199811000-00019","volume":"5","author":"MA Boogaerts","year":"1998","unstructured":"Boogaerts MA. Stem cell transplantation and intensified cytotoxic treatment for myelodysplasia [Review].Curr Opin Hematol. 1998;5:465\u2013471.","journal-title":"Curr Opin Hematol."},{"issue":"suppl 2","key":"BF03165082_CR14","first-page":"29","volume":"15","author":"A Pagliuca","year":"1995","unstructured":"Pagliuca A, Mijovic A, Jeanes A, Perry A, Mufti GJ. Delayed platelet regeneration following allogeneic peripheral blood progenitor cell transplantation for acute leukemia [abstract].Bone Marrow Transplant. 1995;15(suppl 2):S29","journal-title":"Bone Marrow Transplant."},{"key":"BF03165082_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bmt.1701084","volume":"21","author":"V Runde","year":"1998","unstructured":"Runde V, De Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant. 1998;21:255\u2013261.","journal-title":"Bone Marrow Transplant."},{"key":"BF03165082_CR16","first-page":"1573","volume-title":"Hematology: Basic Principles and Practice","author":"MM Horowitz","year":"2000","unstructured":"Horowitz MM. Results of allogeneic stem cell transplantation for malignant disorders. In: Hoffman R, Benz EJ, Shattil SJ, et al. eds.Hematology: Basic Principles and Practice. New York: Churchill Livingstone. 2000:1573\u20131587."},{"key":"BF03165082_CR17","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-112-8-590","volume":"112","author":"FR Appelbaum","year":"1990","unstructured":"Appelbaum FR, Barrall J, Storb R, et al. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome.Ann. Intern. Med. 1990;112:590\u2013597.","journal-title":"Ann. Intern. Med."},{"key":"BF03165082_CR18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1200\/JCO.1996.14.1.220","volume":"14","author":"JE Anderson","year":"1996","unstructured":"Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.J Clin Oncol. 1996;14:220\u2013226.","journal-title":"J Clin Oncol."},{"key":"BF03165082_CR19","doi-asserted-by":"crossref","unstructured":"Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.Biol Blood and Marrow Transplantation. (In Press)","DOI":"10.1053\/bbmt.2002.v8.pm11939606"},{"key":"BF03165082_CR20","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0145-2126(99)00073-9","volume":"23","author":"JE Anderson","year":"1999","unstructured":"Anderson JE, Appelbaum FR, Deeg HJ, Storb R. Phase II study of busulfan (BU) and total body irradiation (TBI) as a novel preparative regimen in allogenic marrow transplantation (BMT) for advanced myelodysplastic syndromep [abstract].Leuk Res. 1999;23:S83-S85.","journal-title":"Leuk Res."},{"key":"BF03165082_CR21","unstructured":"Guardiola P, Runde V, Bacigalupo A, et al. A retrospective comparison of bone marrow and G-CSF mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes.Blood. (In Press)"},{"key":"BF03165082_CR22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.2000.02133.x","volume":"110","author":"DY Zang","year":"2000","unstructured":"Zang DY, Deeg HJ, Gooley T, et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation.Br J Haematol. 2000;110:217\u2013222.","journal-title":"Br J Haematol."},{"key":"BF03165082_CR23","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.bmt.1701781","volume":"23","author":"RM Sobecks","year":"1999","unstructured":"Sobecks RM, Le Beau MM, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.Bone Marrow Transplant. 1999;23:1161\u20131165.","journal-title":"Bone Marrow Transplant"},{"key":"BF03165082_CR24","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.1999.17.10.3128","volume":"17","author":"JW Friedberg","year":"1999","unstructured":"Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-hodgkin\u2019s lymphoma.J Clin Oncol. 1999;17:3128\u20133135.","journal-title":"J Clin Oncol."},{"key":"BF03165082_CR25","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.bmt.1701269","volume":"21","author":"R Arnold","year":"1998","unstructured":"Arnold R, De Witte T, van Biezen A, et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.Bone Marrow Transplant. 1998;21:1213\u20131216.","journal-title":"Bone Marrow Transplant."},{"key":"BF03165082_CR26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ajcp\/108.4.369","volume":"108","author":"CS Wilson","year":"1997","unstructured":"Wilson CS, Traweek ST, Slovak ML, Niland JC, Forman SJ, Brynes RK. Myelodysplastic syndrome occurring after autologous bone marrow transplantation for lymphoma. Morphologic features.Am J Clin Pathol. 1997;108:369\u2013377.","journal-title":"Am J Clin Pathol."},{"key":"BF03165082_CR27","first-page":"75","volume":"9","author":"T Witte De","year":"1999","unstructured":"De Witte T. Stem cell transplantation in myelodysplastic syndromes [Review].Forum. 1999;9:75\u201381.","journal-title":"Forum."},{"key":"BF03165082_CR28","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2001.19.8.2134","volume":"19","author":"RP Witherspoon","year":"2001","unstructured":"Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, Appelbaum FR. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia.J Clin Oncol. 2001;19:2134\u20132141.","journal-title":"J Clin Oncol."},{"key":"BF03165082_CR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bmt.1701517","volume":"23","author":"AM Leahey","year":"1999","unstructured":"Leahey AM, Friedman DL, Bunin NJ. Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia.Bone Marrow Transplant. 1999;23:21\u201325.","journal-title":"Bone Marrow Transplant"},{"key":"BF03165082_CR30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bmt.1700971","volume":"20","author":"KK Ballen","year":"1997","unstructured":"Ballen KK, Gilliland DG, Guinan EC, et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia.Bone Marrow Transplant. 1997; 20:737\u2013743.","journal-title":"Bone Marrow Transplant."},{"issue":"suppl 1","key":"BF03165082_CR31","first-page":"S25","volume":"12","author":"FR Appelbaum","year":"1998","unstructured":"Appelbaum FR, Anderson J. Allogeneic bone marrow transplantion for myelodysplastic syndrome: outcomes analysis according to IPSS score.Leukemia. 1998;12(suppl 1):S25-S29.","journal-title":"Leukemia"},{"key":"BF03165082_CR32","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V92.6.1910","volume":"92","author":"TJ Nevill","year":"1998","unstructured":"Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation.Blood. 1998;92:1910\u20131917.","journal-title":"Blood."},{"key":"BF03165082_CR33","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","volume":"67","author":"C Rozman","year":"1991","unstructured":"Rozman C, Giralt M, Feliu E, Rubio D, Cortes M-T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders.Cancer. 1991;67:2658\u20132663.","journal-title":"Cancer"},{"key":"BF03165082_CR34","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B Dupriez","year":"1996","unstructured":"Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.Blood. 1996;88:1013\u20131018.","journal-title":"Blood"},{"key":"BF03165082_CR35","first-page":"2831","volume":"93","author":"P Guardiola","year":"1999","unstructured":"Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European group for blood and marrow transplantation, Socit Franaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study.Blood. 1999;93:2831\u20132838.","journal-title":"Blood."},{"issue":"Part 1","key":"BF03165082_CR36","first-page":"856a","volume":"98","author":"HJ Deeg","year":"2001","unstructured":"Deeg HJ, Platzbecker U, Sale GE, et al. Allogeneic hemopoietic stem cell transplantation for myelofibrosis [abstract].Blood. 2001;98(Part 1):856a-857a.","journal-title":"Blood"},{"key":"BF03165082_CR37","doi-asserted-by":"crossref","unstructured":"Platzbecker U, Gooley T, Anasetti C, et al. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation.Leuk Lymphoma. (In Press)","DOI":"10.1080\/1042819022386626"},{"key":"BF03165082_CR38","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V95.4.1188.004k38_1188_1194","volume":"95","author":"HJ Deeg","year":"2000","unstructured":"Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.Blood. 2000;95:1188\u20131194.","journal-title":"Blood."},{"key":"BF03165082_CR39","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1046\/j.1365-2141.1998.01042.x","volume":"103","author":"L Castagna","year":"1998","unstructured":"Castagna L, El Weshi A, Bourhis JH, et al. Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT) [letter].Br J Haematol. 1998;103:284\u2013285.","journal-title":"Br J Haematol."},{"key":"BF03165082_CR40","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/sj.leu.2401581","volume":"13","author":"P Bader","year":"1999","unstructured":"Bader P, Klingebiel T, Schaudt A, et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.Leukemia. 1999;13:2079\u20132086.","journal-title":"Leukemia"},{"key":"BF03165082_CR41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.bmt.1702204","volume":"25","author":"AM Carella","year":"2000","unstructured":"Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans (Editorial).Bone Marrow Transplant. 2000;25:345\u2013350.","journal-title":"Bone Marrow Transplant"},{"key":"BF03165082_CR42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/bbmt.1999.v5.pm10465099","volume":"5","author":"PA McSweeney","year":"1999","unstructured":"McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications [Review].Biol Blood Marrow Transplant. 1999;5:192\u2013203.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF03165082_CR43","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1016\/S0041-1345(00)01785-1","volume":"32","author":"R Storb","year":"2000","unstructured":"Storb R, McSweeney PA, Sandmaier BM, et al. Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the 21st century.Transplant Proc. 2000;32:2548\u20132549.","journal-title":"Transplant Proc."},{"key":"BF03165082_CR44","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","volume":"98","author":"IF Khouri","year":"2001","unstructured":"Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.Blood. 2001;98:3595\u20133599.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03165082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03165082\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03165082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T16:25:39Z","timestamp":1590164739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03165082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":44,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["BF03165082"],"URL":"https:\/\/doi.org\/10.1007\/bf03165082","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}